<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="antithesis" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">5. Tropism of YFV</segment>
<segment id="2" parent="1002" relname="joint">In humans , after transcutaneous inoculation , YFV exhibits broad patterns of tissue tropism</segment>
<segment id="3" parent="1002" relname="joint">and is disseminated systemically via infection of multiple white cell subsets .</segment>
<segment id="4" parent="1004" relname="span">With respect to organ tropism , the liver is the primary target ,</segment>
<segment id="5" parent="4" relname="concession">although the heart , kidneys , liver , spleen , and less frequently , the brain tissue , can support YFV replication .</segment>
<segment id="6" parent="1006" relname="span">The natural host range of YFV includes humans , non-human primates and mosquitos .</segment>
<segment id="7" parent="1007" relname="joint">Additionally , wild animals from the diverse orders Artiodactyla , Carnivora and the superorder Xenarthra have been reported to be serologically positive for anti-YFV antibodies ,</segment>
<segment id="8" parent="1008" relname="span">and the elicitation of antibody responses against YFV indicates a potentially productive infection within these species ,</segment>
<segment id="9" parent="1009" relname="span">indicating that diverse mammalian species could represent YFV potential reservoirs</segment>
<segment id="10" parent="9" relname="elaboration">( see Section 8.3 ) .</segment>
<segment id="11" parent="1011" relname="preparation">Mouse Models for YFV</segment>
<segment id="12" parent="1012" relname="span">YFV research is currently limited</segment>
<segment id="13" parent="12" relname="circumstance">as it remains challenging and expensive to establish workflows with non-human primates .</segment>
<segment id="14" parent="1015" relname="concession">While YFV has a limited host species-tropism ,</segment>
<segment id="15" parent="1015" relname="span">artificial infection of laboratory mice and hamsters is possible ,</segment>
<segment id="16" parent="1016" relname="span">although the course of disease differs from that</segment>
<segment id="17" parent="16" relname="elaboration">observed in humans .</segment>
<segment id="18" parent="1011" relname="joint">Nevertheless , a number of studies in genetically modified or humanized mice have yielded insights into YFV infection and dissemination in vivo .</segment>
<segment id="19" parent="1019" relname="span">Single cell-tracking of YFV-17D dissemination in different mouse models</segment>
<segment id="20" parent="21" relname="attribution">identified novel YFV replication reservoirs in secondary lymphoid compartments ,</segment>
<segment id="21" parent="1020" relname="span">with hematopoietic STAT1 knockout increasing virus-induced pathogenicity .</segment>
<segment id="22" parent="1023" relname="span">Double-humanized mice have been developed ,</segment>
<segment id="23" parent="22" relname="elaboration">possessing both human immune systems and hepatocytes ,</segment>
<segment id="24" parent="1024" relname="span">and these animals represent ideal tools</segment>
<segment id="25" parent="1025" relname="span">for monitoring systemic YFV infection in vivo</segment>
<segment id="26" parent="25" relname="circumstance">as both compartments are permissive for YFV .</segment>
<segment id="27" parent="1011" relname="joint">In addition to hepatotropism ,</segment>
<segment id="28" parent="1011" relname="joint">YFV can also be neurotropic in rodents , primates and humans .</segment>
<segment id="29" parent="1030" relname="span">In contrast to polio virus and reovirus ,</segment>
<segment id="30" parent="29" relname="elaboration">which infect the brain via the CNS ,</segment>
<segment id="31" parent="1031" relname="span">YFV-17D infects brain tissue</segment>
<segment id="32" parent="31" relname="means">by crossing the blood-brain barrier .</segment>
<segment id="33" parent="1036" relname="span">A mouse-neurovirulent strain</segment>
<segment id="34" parent="33" relname="restatement">( SPYF )</segment>
<segment id="35" parent="1036" relname="elaboration">based on the Porterfield 17D</segment>
<segment id="36" parent="1035" relname="elaboration">( PYF17D ) strain</segment>
<segment id="37" parent="1037" relname="span">was derived by additional passaging in SCID mice ,</segment>
<segment id="38" parent="37" relname="elaboration">exhibiting enhanced neurovirulence and neuroinvasiveness .</segment>
<segment id="39" parent="1011" relname="joint">This enhanced neurotopism was correlated with 13 amino acid substitutions ,</segment>
<segment id="40" parent="1040" relname="span">five of which were located in the E protein .</segment>
<segment id="41" parent="1042" relname="span">Arboviruses can encounter dissemination barriers in mosquitos ,</segment>
<segment id="42" parent="41" relname="elaboration">restricting the spreading of the virus within the vector species .</segment>
<segment id="43" parent="1044" relname="span">These include innate immunity related pathways as well as physical tissue barriers</segment>
<segment id="44" parent="43" relname="elaboration">associated with the midgut and salivary glands .</segment>
<segment id="45" parent="1045" relname="same_unit">However ,</segment>
<segment id="46" parent="1047" relname="circumstance">while patterns of YFV-17D dissemination in immunocompetent mice were restricted ,</segment>
<segment id="47" parent="1047" relname="span">infection of IFNAR knockout mice resulted in broad dissemination</segment>
<segment id="48" parent="1049" relname="attribution">preceding viral clearance ,</segment>
<segment id="49" parent="50" relname="attribution">indicating</segment>
<segment id="50" parent="1049" relname="span">that no barriers to dissemination exist in the absence of type I IFN .</segment>
<segment id="51" parent="1051" relname="same_unit">Furthermore ,</segment>
<segment id="52" parent="1053" relname="concession">while I and II type IFNs contribute to control of YFV-17D infection ,</segment>
<segment id="53" parent="1053" relname="joint">type III IFN was demonstrated to have immunomodulatory functions</segment>
<segment id="54" parent="1053" relname="joint">and was protective against YFV-17D neuroinvasion in mouse models .</segment>
<segment id="55" parent="1056" relname="preparation">YFD-17D infection of IFN-α/β receptor and STAT1 signaling molecule deficient mice resulted in systemic viscerotropic infection :</segment>
<segment id="56" parent="1057" relname="span">a course of disease</segment>
<segment id="57" parent="1058" relname="span">which resembles that</segment>
<segment id="58" parent="1059" relname="span">observed in humans</segment>
<segment id="59" parent="58" relname="antithesis">rather than the typical encephalitic disease course</segment>
<segment id="60" parent="1057" relname="elaboration">commonly reported for mice .</segment>
<segment id="61" parent="1061" relname="span">Finally ,</segment>
<segment id="62" parent="1062" relname="span">while many flaviviruses share the common ability</segment>
<segment id="63" parent="1063" relname="joint">to antagonize IFN signaling</segment>
<segment id="64" parent="1065" relname="attribution">and therefore enhance viral replication ,</segment>
<segment id="65" parent="1065" relname="span">the YFV NS5 is unable to bind murine STAT2</segment>
<segment id="66" parent="65" relname="elaboration">and in contrast to ZIKV and DENV , is unable to engage human STAT2 in murine cells .</segment>
<segment id="67" parent="1067" relname="span">Murine STAT2 was demonstrated to repress YFV replication in murine cells ,</segment>
<segment id="68" parent="67" relname="elaboration">which was correlated with an absence of IFN-α/β-mediated NS5 ubiquitination .</segment>
<segment id="69" parent="1011" relname="joint">Together , these mouse studies enhance our understanding of YFV dissemination and host control in vivo .</segment>
<segment id="70" parent="1070" relname="span">These findings are useful for the development of the next generation of small animal disease models for YFV ,</segment>
<segment id="71" parent="1071" relname="span">which should endeavor to recapitulate the disease course</segment>
<segment id="72" parent="71" relname="elaboration">seen in humans .</segment>
<segment id="73" parent="1073" relname="span">Thus , the generation of an immunocompetent mouse model would be beneficial ,</segment>
<segment id="74" parent="1074" relname="span">which could be realized</segment>
<segment id="75" parent="1076" relname="span">by knocking out downstream specific anti-YFV effectors</segment>
<segment id="76" parent="75" relname="elaboration">that directly inhibit differential aspects of the YFV lifecycle ,</segment>
<segment id="77" parent="1076" relname="antithesis">rather than upstream master-regulators of the antiviral response .</segment>
<segment id="78" parent="1073" relname="elaboration">Screening approaches could identify such factors .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1003" relname="background"/>
<group id="1003" type="multinuc" parent="1001" relname="span"/>
<group id="1004" type="span" parent="1003" relname="joint"/>
<group id="1006" type="span" parent="1003" relname="joint"/>
<group id="1007" type="multinuc" parent="6" relname="elaboration"/>
<group id="1008" type="span" parent="1007" relname="joint"/>
<group id="1009" type="span" parent="8" relname="elaboration"/>
<group id="1010" type="span" parent="1003" relname="joint"/>
<group id="1011" type="multinuc" parent="1010" relname="span"/>
<group id="1012" type="span" parent="1011" relname="joint"/>
<group id="1014" type="span" parent="1011" relname="joint"/>
<group id="1015" type="span" parent="1014" relname="span"/>
<group id="1016" type="span" parent="15" relname="concession"/>
<group id="1019" type="span" parent="1011" relname="joint"/>
<group id="1020" type="span" parent="19" relname="elaboration"/>
<group id="1023" type="span" parent="1011" relname="joint"/>
<group id="1024" type="span" parent="1011" relname="joint"/>
<group id="1025" type="span" parent="24" relname="purpose"/>
<group id="1029" type="multinuc" parent="1011" relname="joint"/>
<group id="1030" type="span" parent="1029" relname="same_unit"/>
<group id="1031" type="span" parent="1029" relname="same_unit"/>
<group id="1033" type="multinuc" parent="1011" relname="joint"/>
<group id="1034" type="span" parent="1033" relname="same_unit"/>
<group id="1035" type="span" parent="1034" relname="span"/>
<group id="1036" type="span" parent="1035" relname="span"/>
<group id="1037" type="span" parent="1033" relname="same_unit"/>
<group id="1040" type="span" parent="1011" relname="joint"/>
<group id="1041" type="span" parent="40" relname="elaboration"/>
<group id="1042" type="span" parent="1041" relname="span"/>
<group id="1043" type="multinuc" parent="1042" relname="elaboration"/>
<group id="1044" type="span" parent="1043" relname="contrast"/>
<group id="1045" type="multinuc" parent="1043" relname="contrast"/>
<group id="1046" type="span" parent="1045" relname="same_unit"/>
<group id="1047" type="span" parent="1046" relname="span"/>
<group id="1048" type="span" parent="47" relname="elaboration"/>
<group id="1049" type="span" parent="1048" relname="span"/>
<group id="1051" type="multinuc" parent="1011" relname="joint"/>
<group id="1052" type="span" parent="1051" relname="same_unit"/>
<group id="1053" type="multinuc" parent="1052" relname="span"/>
<group id="1055" type="span" parent="1011" relname="joint"/>
<group id="1056" type="span" parent="1055" relname="span"/>
<group id="1057" type="span" parent="1056" relname="span"/>
<group id="1058" type="span" parent="56" relname="elaboration"/>
<group id="1059" type="span" parent="57" relname="elaboration"/>
<group id="1061" type="span" parent="1011" relname="joint"/>
<group id="1062" type="span" parent="61" relname="concession"/>
<group id="1063" type="multinuc" parent="62" relname="purpose"/>
<group id="1064" type="span" parent="1063" relname="joint"/>
<group id="1065" type="span" parent="1064" relname="span"/>
<group id="1067" type="span" parent="1011" relname="joint"/>
<group id="1070" type="span" parent="1011" relname="joint"/>
<group id="1071" type="span" parent="70" relname="elaboration"/>
<group id="1072" type="span" parent="1011" relname="joint"/>
<group id="1073" type="span" parent="1072" relname="span"/>
<group id="1074" type="span" parent="73" relname="elaboration"/>
<group id="1075" type="span" parent="74" relname="means"/>
<group id="1076" type="span" parent="1075" relname="span"/>
	</body>
</rst>
